文献速递产科母胎医学

早发型子痫前期、血浆microRNA与内皮细胞功能

Early-onset preeclampsia, plasma microRNAs, and endothelial cell function.
PubMed 文献 · Am J Obstet Gynecol · 2019-12-10

该研究比较了早发型子痫前期、健康孕妇和非妊娠妇女的血浆miRNA浓度,发现子痫前期与健康妊娠之间有26种miRNA存在差异,其中miR-574-5p、miR-1972和miR-4793-3p升高最显著;体外实验显示这些miRNA可影响内皮细胞功能。

要点

  • 早发型子痫前期患者血浆中26种miRNA浓度与健康妊娠不同。
  • miR-574-5p、miR-1972、miR-4793-3p在子痫前期中升高最显著。
  • miR-574-5p和miR-1972可降低内皮细胞增殖和/或迁移及成管能力。

核心结论

  • 早发型子痫前期患者血浆miRNA浓度与健康妊娠不同。
  • miR-574-5p和miR-1972可能通过降低MKI67表达来降低内皮细胞增殖和/或迁移及成管能力。
  • 这些miRNA可能是子痫前期中影响内皮细胞的抗血管生成因子。

研究设计与样本

  • 比较早发型子痫前期妇女、孕龄匹配的健康孕妇和非妊娠妇女的血浆样本中3391种(前体)miRNA浓度,使用miRNA 3.1芯片(Affymetrix)并用实时定量聚合酶链反应验证。
  • 将人脐静脉内皮细胞转染miRNA模拟物(选择在子痫前期与健康妊娠中倍数变化最大且错误发现率最低的3种miRNA),进行功能实验(伤口愈合实验、增殖实验和成管实验)。
  • 通过基因表达芯片(Genechip Human Gene 2.1 ST arrays)分析转染内皮细胞的基因表达,并用实时定量聚合酶链反应在个体样本中验证差异表达基因。

主要发现

  • 健康孕妇与非妊娠妇女之间血浆miRNA浓度无显著差异(倍数变化<-1.2或>1.2且错误发现率<0.05)。
  • 子痫前期与健康妊娠之间有26种(前体)miRNA血浆浓度不同。
  • 在子痫前期与健康妊娠中倍数变化最大且错误发现率最低的3种升高miRNA为miR-574-5p、miR-1972和miR-4793-3p。
  • 转染miR-574-5p降低伤口愈合能力(P<.05)并倾向于降低增殖(P<.1);转染miR-1972降低成管能力(P<.05)并倾向于降低增殖(P<.1);转染miR-4793-3p倾向于降低伤口愈合能力和成管能力(P<.1)。
  • 转染miR-574-5p倾向于降低增殖标志物MKI67的表达(P<.1)。

关键数值与推荐

  • 血浆miRNA浓度差异定义为倍数变化<-1.2或>1.2且错误发现率<0.05。
  • 共比较3391种(前体)miRNA浓度。
  • 子痫前期与健康妊娠之间有26种(前体)miRNA血浆浓度不同。
  • 在子痫前期中升高最显著的3种miRNA为miR-574-5p、miR-1972和miR-4793-3p。
  • 功能实验的显著性阈值为P<.05,趋势性阈值为P<.1。

临床怎么用

  • 早发型子痫前期患者血浆miRNA谱与健康妊娠不同,差异miRNA可能作为潜在的生物标志物。
  • miR-574-5p和miR-1972在体外可影响内皮细胞功能,可能参与子痫前期的抗血管生成机制。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia is a hypertensive pregnancy disorder in which generalized systemic inflammation and maternal endothelial dysfunction are involved in the pathophysiology. MiRNAs are small noncoding RNAs responsible for post-transcriptional regulation of gene expression and involved in many physiological processes. They mainly downregulate translation of their target genes. OBJECTIVE: We aimed to compare the plasma miRNA concentrations in preeclampsia, healthy pregnant women, and nonpregnant women. Furthermore, we aimed to evaluate the effect of 3 highly increased plasma miRNAs in preeclampsia on endothelial cell function in vitro. STUDY DESIGN: We compared 3391 (precursor) miRNA concentrations in plasma samples from early-onset preeclamptic women, gestational age-matched healthy pregnant women, and nonpregnant women using miRNA 3.1. arrays (Affymetrix) and validated our findings by real-time quantitative polymerase chain reaction. Subsequently, endothelial cells (human umbilical vein endothelial cells) were transfected with microRNA mimics (we choose the 3 miRNAs with the greatest fold change and lowest false-discovery rate in preeclampsia vs healthy pregnancy). After transfection, functional assays were performed to evaluate whether overexpression of the microRNAs in endothelial cells affected endothelial cell function in vitro. Functional assays were the wound-healing assay (which measures cell migration and proliferation), the proliferation assay, and the tube-formation assay (which assesses formation of endothelial cell tubes during the angiogenic process). To determine whether the miRNAs are able to decrease gene expression of certain genes, RNA was isolated from transfected endothelial cells and gene expression (by measuring RNA expression) was evaluated by gene expression microarray (Genechip Human Gene 2.1 ST arrays; Life Technologies). For the microarray, we used pooled samples, but the differently expressed genes in the microarray were validated by real-time quantitative polymerase chain reaction in individual samples. RESULTS: No significant differences (fold change <-1.2 or >1.2 with a false-discovery rate <0.05) were found in miRNA plasma concentrations between healthy pregnant and nonpregnant women. The plasma concentrations of 26 (precursor) miRNAs were different between preeclampsia and healthy pregnancy. The 3 miRNAs that were increased with the greatest fold change and lowest false-discovery rate in preeclampsia vs healthy pregnancy were miR-574-5p, miR-1972, and miR-4793-3p. Transfection of endothelial cells with these miRNAs in showed that miR-574-5p decreased (P<.05) the wound-healing capacity (ie, decreased endothelial cell migration and/or proliferation) and tended (P<.1) to decrease proliferation, miR-1972 decreased tube formation (P<.05), and also tended (P<.1) to decrease proliferation, and miR-4793-3p tended (P<.1) to decrease both the wound-healing capacity and tube formation in vitro. Gene expression analysis of transfected endothelial cells revealed that miR-574-5p tended (P<.1) to decrease the expression of the proliferation marker MKI67. CONCLUSION: We conclude that in the early-onset preeclampsia group in our study different concentrations of plasma miRNAs are present as compared with healthy pregnancy. Our results suggest that miR-574-5p and miR-1972 decrease the proliferation (probably via decreasing MKI67) and/or migration as well as the tube-formation capacity of endothelial cells. Therefore, these miRNAs may be antiangiogenic factors affecting endothelial cells in preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lip SV, Boekschoten MV, Hooiveld GJ, et al. Early-onset preeclampsia, plasma microRNAs, and endothelial cell function. Am J Obstet Gynecol. 2019. PMID: 31836544. doi:10.1016/j.ajog.2019.11.1286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。